BioMarin Q2 GAAP net income drops 81% to $45 million; revenue rises 20% to $990 million
BMRN•Second-quarter results
- BioMarin Q2 revenue rose 20% year over year to USD 990 million; GAAP net income fell 81% to USD 45 million.
- Non-GAAP diluted EPS slipped 17% to USD 1.2; non-GAAP operating margin narrowed 3.5 percentage points to 36.4%.
- VOXZOGO revenue increased 14% to USD 253 million; Metabolic Conditions revenue climbed 25% to USD 695 million.
Outlook and cost reductions
- Management cited rapid integration of Amicus; BioMarin targets about USD 280 million in GAAP cost reductions, fully realized in 2028.
- Raised 2026 guidance: revenue USD 3.88 billion to USD 3.93 billion; VOXZOGO USD 1 billion to USD 1.05 billion; non-GAAP diluted EPS USD 4.9 to USD 5.1.
